Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The acute GH release stimulated by the synthetic hexapeptide, His-DTrp-Ala-Trp-DPhe-Lys-NH2 [GH releasing peptide (GHRP)], was determined in 18 normal men and compared with the effects of GH-releasing hormone, GHRH-(1-44)-NH2.

No adverse clinical effects of laboratory abnormalities were observed in response to GHRP.

Who Took Part

According to the abstract, 18 men were involved.

The age groups tagged for this paper are adults, men only.

Specificity of effect was assessed by measurement of serum PRL, LH, TSH, and cortisol.

How the Study Was Run

In design terms this was a placebo-controlled study.

Some men received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

The subject headings attached to it are Drug Synergism, Growth Hormone, Growth Hormone-Releasing Hormone, Hydrocortisone, Luteinizing Hormone, Oligopeptides and Prolactin.

What This Means in Plain Language

The paper is a placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 18 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.